Export 19 results:
Autore Titolo [ Tipo(Asc)] Anno
Filtri: Autore è Celeghini, Claudio  [Clear All Filters]
Journal Article
Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.
Celeghini C, Not T, Norcio A, Monasta L, Secchiero P. Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. Exp Ther Med 2014;8(6):1906-1908.
Rimondi E, di Iasio MGrazia, Gonelli A, Celeghini C, Secchiero P, Zauli G. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.
Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int J Mol Sci 2016;17(3):365.
Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. J Med Chem 2015;
Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G. Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry. Mediators Inflamm 2014;2014:306848.
Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.

Amministrazione Trasparente